The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Adjuvant cancer treatments such as chemotherapy and radiation are given after a primary cancer treatment to help prevent ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Aethlon Medical receives Ethics Committee approval for Hemopurifier cancer trial in India: San Diego Saturday, September 21, 2024, 09:00 Hrs [IST] Aethlon Inc., a medical therapeu ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...